Transdermal Testosterone Nanoemulsion in Women Libido
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled study. Seventy women, aged 35-75
years, with treatment-emergent loss of libido will be randomly allocated to the treatment
with a Transdermal nanoemulsion of Testosterone (500mcg) delivering 300 mcg of
testosterone/day or an identical placebo nanoemulsion (PLA) for 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University Potiguar
Collaborators:
CURAPROX Farmacias Evidence Ltda INTEGRAL MÉDICA Suplementos LAB VITRUS laboratório de Análises Clínicas Lemos laboratório de Análises Clínicas